Abstract :
BCL-2 antiapoptotic proteins are considered ripe targets for anticancer drugs, yet only recently have small molecule inhibitors emerged. Beccatini and colleagues find a BCL-XL inhibitor in the guise of a familiar natural product, gossypol. An analog, apogossypol, is a relatively selective BCL-XL antagonist.
